Patent ID: 11931335
Assignee: AMAZENTIS SA
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 9:
10. A method of treating a disease selected from the group consisting of muscle degenerative disorder, sarcopenia, muscular dystrophy, cardiomyopathy, Ulrich myopathy, obesity, cardiovascular disease, atherosclerosis, a mitochondria-related disease associated with altered mitochondrial function or a reduced mitochondrial density; or disease related to a metabolic function, comprising:
conjointly administering to a vertebrate in need thereof an effective amount of L-carnitine or a pharmaceutically acceptable salt thereof, and a urolithin represented by Formula I or a pharmaceutically acceptable salt thereof;, , wherein:
R1, R2, R3, R4, R5, R6, R7, and R8 are independently selected from the group consisting of H and OR; and
R is independently for each occurrence H, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl.